Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$130,700.00
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies
EF 2025-26 · 2025-08-01
Résumé
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet medical need in rare ophthalmological diseases, including Stargardt Disease. The project will evaluate novel DNA based genetic medicines, encapsulated with Entos’ Fusogenix PLV formulations, for enhanced bioactivity, durable transgene expression and optimal tolerability in small animal models.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2027-03-31
Agreement Number
1034236
Agreement Start Date
2025-08-01
Agreement Title
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies
Agreement Title (French)
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Développement de thérapies géniques non virales ciblées in vivo
Agreement Type
Contribution
Agreement Value
$130,700.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet medical need in rare ophthalmological diseases, including Stargardt Disease. The project will evaluate novel DNA based genetic medicines, encapsulated with Entos’ Fusogenix PLV formulations, for enhanced bioactivity, durable transgene expression and optimal tolerability in small animal models.
Description (French)
Dans le cadre du projet de consortium international «NPmsDNA2024 : Développement de thérapies géniques non virales ciblées in vivo», ce projet se concentrera sur l’utilisation des formulations Fusogenix PLV d’Entos, optimisées pour l’administration de médicaments génétiques à base d’ADN à des types de cellules cibles de la rétine, afin de répondre aux besoins médicaux non satisfaits dans le domaine des maladies ophtalmologiques rares, y compris la maladie de Stargardt. Le projet évaluera de nouveaux médicaments génétiques à base d’ADN, encapsulés dans les formulations Fusogenix PLV d’Entos, pour une meilleure bioactivité, une expression durable du transgène et une tolérance optimale dans des modèles de petits animaux.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2025-2026-Q2-1034236
